Journal of Clinical Oncology, Vol 14, 1136-1145, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration

JL Misset, M di Palma, M Delgado, R Plagne, P Chollet, P Fumoleau, B Le Mevel, D Belpomme, J Guerrin, P Fargeot, R Metz, M Ithzaki, C Hill and G Mathe
Service des Maladies Sanguines et Tumorales Hopital Paul Brousse, Villejuif, France.

PURPOSE: To determine the long-term impact on disease-free survival (DFS) and overall survival (OS) of adjuvant anthracycline-based chemotherapy, when prospectively compared by random allocation with standard cyclophosphamide, methotrexate, and fluorouracil (CMF) in node- positive (N+) breast cancer patients. PATIENTS AND METHODS: Two hundred forty-nine patients with N+ breast cancer, recruited from eight French cancer centers, were randomized to receive 12 monthly cycles of adjuvant chemotherapy, either CMF (n = 112) or doxorubicin, vincristine, cyclophosphamide, and fluorouracil (AVCF) (n = 136). All had a negative metastatic work-up before inclusion, which was stratified by accrual center, tumor stage (International Union Against Cancer [UICC]), and menopausal status. RESULTS: No severe adverse effect related to grade 4 (World Health Organization [WHO]) toxicity was observed. There was no difference in second primary tumor incidence between the two arms. The treatment given was 88% of planned for AVCF and 75% for CMF in both premenopausal and menopausal patients. With a median follow-up time of 16 years (range, 13 to 17), the OS and DFS rates are significantly longer in the AVCF arm (56% v 41% [P = .01] for OS, and 53% v 36% [P = .006] for DFS). These differences are significant, irrespective of tumor stage (T1 to T2 v T3 to T4), and remain positive in patients with or without postoperative locoregional radiotherapy (55% of cohort). When analyzed according to menopausal status, the differences remain significant only for premenopausal patients. CONCLUSION: This set of mature controlled data confirms the added value of anthracycline-based combination adjuvant therapy for N+ breast cancer patients when compared with CMF, with both regimens given for 1 year.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Robson and S. Verma Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era? Oncologist, October 1, 2009; 14(10): 950 - 958. [Abstract] [Full Text] [PDF]

				H. Roche, P. Kerbrat, J. Bonneterre, P. Fargeot, P. Fumoleau, A. Monnier, P. Clavere, M.-J. Goudier, P. Chollet, J.-P. Guastalla, et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial Ann. Onc., August 1, 2006; 17(8): 1221 - 1227. [Abstract] [Full Text] [PDF]

				L. F. Hutchins, S. J. Green, P. M. Ravdin, D. Lew, S. Martino, M. Abeloff, A. P. Lyss, C. Allred, S. E. Rivkin, and C. K. Osborne Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102 J. Clin. Oncol., November 20, 2005; 23(33): 8313 - 8321. [Abstract] [Full Text] [PDF]

				G. Cocconi, B. Di Blasio, C. Boni, G. Bisagni, E. Rondini, M. A. Bella, F. Leonardi, L. Savoldi, C. Vallisneri, R. Camisa, et al. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes Ann. Onc., September 1, 2005; 16(9): 1469 - 1476. [Abstract] [Full Text] [PDF]

				M. Campone, H. Roche, P. Kerbrat, J. Bonneterre, P. Romestaing, P. Fargeot, M. Namer, A. Monnier, P. Montcuquet, M.-J. Goudier, et al. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group Ann. Onc., August 1, 2005; 16(8): 1343 - 1351. [Abstract] [Full Text] [PDF]

				W. L. Allen and P. G. Johnston Role of Genomic Markers in Colorectal Cancer Treatment J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552. [Abstract] [Full Text] [PDF]

				C. Alliot Weekly Epirubicin Plus Tamoxifen Versus Tamoxifen Alone As Adjuvant Treatment of Operable, Node-Positive, Elderly Breast Cancer Patients J. Clin. Oncol., June 20, 2005; 23(18): 4237 - 4238. [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				A. Dhawan, M. A. Kayani, J. M. Parry, E. Parry, and D. Anderson Aneugenic and clastogenic effects of doxorubicin in human lymphocytes Mutagenesis, November 1, 2003; 18(6): 487 - 490. [Abstract] [Full Text] [PDF]

				N. Shikama, S. Sasaki, M. Mitsumori, M. Hiraoka, C. Yamauchi, T. Yamamoto, T. Teshima, and T. Inoue Patterns of Care Study in Japan: Analysis of Patients Subjected to Mastectomy Followed by Radiotherapy Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 456 - 462. [Abstract] [Full Text] [PDF]

				D. C. Dale, G. C. McCarter, J. Crawford, and G. H. Lyman Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical Trials J Natl Compr Canc Netw, July 1, 2003; 1(3): 440 - 454. [Abstract] [PDF]

				C. Bernard-Marty, M. Mano, M. Paesmans, C. Accettura, R. Munoz-Bermeo, T. Richard, K. Kleiber, F. Cardoso, J. P. Lobelle, D. Larsimont, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients Ann. Onc., May 1, 2003; 14(5): 693 - 698. [Abstract] [Full Text] [PDF]

				P. Fumoleau, P. Kerbrat, P. Romestaing, P. Fargeot, A. Bremond, M. Namer, S. Schraub, M.-J. Goudier, J. Mihura, A. Monnier, et al. Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial J. Clin. Oncol., January 15, 2003; 21(2): 298 - 305. [Abstract] [Full Text] [PDF]

				L. Zelek, P. Cottu, M. Tubiana-Hulin, J.-M. Vannetzel, Ph. Chollet, J.-L. Misset, N. Chouaki, M. Marty, E. Gamelin, S. Culine, et al. Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients J. Clin. Oncol., May 15, 2002; 20(10): 2551 - 2558. [Abstract] [Full Text] [PDF]

				A. U. Buzdar, S. E. Singletary, V. Valero, D. J. Booser, N. K. Ibrahim, Z. Rahman, R. L. Theriault, R. Walters, E. Rivera, T. L. Smith, et al. Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer: Preliminary Data of a Prospective Randomized Trial Clin. Cancer Res., May 1, 2002; 8(5): 1073 - 1079. [Abstract] [Full Text] [PDF]

				A. Di Leo, D. Gancberg, D. Larsimont, M. Tanner, T. Jarvinen, G. Rouas, S. Dolci, J.-Y. Leroy, M. Paesmans, J. Isola, et al. HER-2 Amplification and Topoisomerase II{alpha} Gene Aberrations as Predictive Markers in Node-positive Breast Cancer Patients Randomly Treated Either with an Anthracycline-based Therapy or with Cyclophosphamide, Methotrexate, and 5-Fluorouracil Clin. Cancer Res., May 1, 2002; 8(5): 1107 - 1116. [Abstract] [Full Text] [PDF]

				G. N Hortobagyi Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79. [Abstract] [Full Text] [PDF]

				L. J. Pierce Treatment Guidelines and Techniques in Delivery of Postmastectomy Radiotherapy in Management of Operable Breast Cancer J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 117 - 124. [Abstract] [Full Text] [PDF]

				M. J. Piccart, A. Di Leo, M. Beauduin, A. Vindevoghel, J. Michel, C. Focan, A. Tagnon, F. Ries, P. Gobert, C. Finet, et al. Phase III Trial Comparing Two Dose Levels of Epirubicin Combined With Cyclophosphamide With Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer J. Clin. Oncol., June 15, 2001; 19(12): 3103 - 3110. [Abstract] [Full Text] [PDF]

				M.T. Meinardi, D.J. van Veldhuisen, J.A. Gietema, W.V. Dolsma, F. Boomsma, M.P. van den Berg, C. Volkers, J. Haaksma, E.G.E. de Vries, D.Th. Sleijfer, et al. Prospective Evaluation of Early Cardiac Damage Induced by Epirubicin-Containing Adjuvant Chemotherapy and Locoregional Radiotherapy in Breast Cancer Patients J. Clin. Oncol., May 15, 2001; 19(10): 2746 - 2753. [Abstract] [Full Text] [PDF]

				S. P. Ackland, A. Anton, G. P. Breitbach, E. Colajori, J. M. Tursi, C. Delfino, A. Efremidis, A. Ezzat, A. Fittipaldo, K. Kolaric, et al. Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study J. Clin. Oncol., February 15, 2001; 19(4): 943 - 953. [Abstract] [Full Text] [PDF]

				Benefit of a High-Dose Epirubicin Regimen in Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients With Poor Prognostic Factors: 5-Year Follow-Up Results of French Adjuvant Study Group 05 Randomized Trial J. Clin. Oncol., February 1, 2001; 19(3): 602 - 611. [Abstract] [Full Text] [PDF]

				C. Hudis, A. Seidman, J. Baselga, G. Raptis, D. Lebwohl, T. Gilewski, M. Moynahan, N. Sklarin, D. Fennelly, J. P.A. Crown, et al. Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy J. Clin. Oncol., January 1, 1999; 17(1): 93 - 93. [Abstract] [Full Text] [PDF]